List of Excipients in Branded Drug RIOCIGUAT

« Back to Dashboard

Generic Drugs Containing RIOCIGUAT

Company	Ingredient	NDC	Excipient
Zydus Pharmaceuticals USA Inc	riociguat	70710-2156	CELLULOSE, MICROCRYSTALLINE
Zydus Pharmaceuticals USA Inc	riociguat	70710-2156	CROSCARMELLOSE SODIUM
Zydus Pharmaceuticals USA Inc	riociguat	70710-2156	HYDROXYPROPYL CELLULOSE

What are the Most Frequently-Used Excipients in RIOCIGUAT?

# Of NDCs	Excipient
1	CELLULOSE, MICROCRYSTALLINE
1	CROSCARMELLOSE SODIUM
1	HYDROXYPROPYL CELLULOSE

Last updated: October 6, 2026

Riociguat has a commercially attractive excipient profile because it is a low-dose, immediate-release oral tablet with established clinical demand, multiple strengths, and no remaining U.S. new chemical entity exclusivity. The strongest opportunities are generic tablets, Q1/Q2-matched formulations, lactose-free products, high-content uniformity platforms, and differentiated oral delivery systems that improve administration without creating avoidable regulatory risk.

Riociguat Excipient Strategy and Commercial Opportunities

What is riociguat and how is it marketed?

Riociguat is a soluble guanylate cyclase stimulator marketed by Bayer under the brand name Adempas. The FDA approved riociguat in 2013 for:

• Chronic thromboembolic pulmonary hypertension, or CTEPH, after surgical treatment or when surgery is not possible.
• Pulmonary arterial hypertension, or PAH, to improve exercise capacity and reduce clinical worsening risk.

Adempas is supplied as immediate-release tablets in 0.5 mg, 1 mg, 1.5 mg, 2 mg, and 2.5 mg strengths. The recommended dose is titrated three times daily, with a maximum total daily dose of 7.5 mg for adults who tolerate treatment. The drug can be taken with or without food, which reduces food-effect complexity for generic developers (FDA, 2023).

Riociguat is commercially distinct from phosphodiesterase-5 inhibitors because it directly stimulates soluble guanylate cyclase and can remain active when endogenous nitric oxide levels are low. It cannot be coadministered with nitrates, nitric oxide donors, or PDE-5 inhibitors because of the risk of excessive hypotension.

What excipients are used in Adempas tablets?

The U.S. Adempas label identifies a conventional immediate-release tablet platform. The core excipient system includes:

Excipient category	Likely functional role
Lactose monohydrate	Diluent and tablet-mass contributor
Microcrystalline cellulose	Filler, dry binder, compression aid
Crospovidone	Superdisintegrant
Hypromellose	Binder and film-forming polymer
Sodium lauryl sulfate	Wetting and dissolution aid
Magnesium stearate	Lubricant
Film-coat pigments	Strength identification and light protection
Titanium dioxide and coating polymers	Opacity, appearance, and coating performance

The precise composition should be taken from the current national product label and regulatory filing because excipient quantities and coating components can differ by market and manufacturing site. The formulation is not based on a modified-release matrix, lipid system, nanoparticle carrier, or biologic delivery platform (FDA, 2023; Bayer, 2023).

Why does the formulation use multiple tablet strengths?

Riociguat requires dose titration. The five marketed strengths support gradual dose adjustment and allow manufacturers to use color-coded tablets to reduce dispensing errors. A generic developer must therefore control:

• Content uniformity at the 0.5 mg strength.
• Tablet color and visual differentiation.
• Mechanical strength across all dose levels.
• Dissolution consistency after coating.
• Manufacturing yield for low drug-load batches.

The 0.5 mg tablet presents the greatest formulation challenge because the active pharmaceutical ingredient represents a small proportion of total tablet weight. Blend segregation, electrostatic charging, and inadequate sampling can create content-uniformity failures.

What excipient strategy is appropriate for generic riociguat?

A conventional Q1/Q2-matched formulation is the lowest-risk development route for a generic immediate-release riociguat tablet. The formulation should preserve the functional roles of the reference product while allowing modern manufacturing controls.

Core formulation strategy

A practical excipient platform would use:

1. Microcrystalline cellulose or an equivalent compressible diluent.
2. Lactose or a lactose-free alternative.
3. Crospovidone or another rapidly acting superdisintegrant.
4. A low concentration of sodium lauryl sulfate or another wetting agent.
5. Magnesium stearate at a controlled lubrication endpoint.
6. Hypromellose-based film coating with strength-specific pigments.

The main development target is rapid and reproducible dissolution rather than prolonged release. Excessive hydrophobic lubrication, high binder levels, or over-compression could delay drug release and increase bioequivalence risk.

Direct compression versus wet granulation

Direct compression may provide the lowest cost and shortest process route if the riociguat API has acceptable flow, compressibility, and segregation behavior. Wet granulation may offer better content uniformity for the 0.5 mg strength but adds water, drying, process validation, and stability considerations.

A high-shear wet-granulation process could be useful when:

• The API has poor flow.
• The active load is low.
• The blend segregates during transfer.
• The tablet requires greater tensile strength.
• The formulation needs improved content uniformity.

Dry granulation is another option where moisture sensitivity or solvent avoidance limits wet processing. The optimal process depends on API particle-size distribution, bulk density, electrostatic behavior, and solid-state stability.

What are the main excipient risks in riociguat development?

The largest risks are not novel toxicology issues. They are manufacturing and bioequivalence risks associated with a low-dose, highly controlled immediate-release product.

Content uniformity

Low-dose riociguat requires homogeneous distribution across the blend. Developers should evaluate:

• API particle-size reduction.
• Ordered mixing or carrier-based blending.
• Blend sampling plans.
• Segregation during hopper discharge.
• Transfer-line residence time.
• Tablet weight variation.
• Assay by individual dosage unit.

A larger tablet with a lower drug concentration can improve process robustness, but it may reduce patient convenience and depart from the reference product's dimensions.

Dissolution

Sodium lauryl sulfate can improve wetting, but excessive surfactant may alter dissolution behavior, tablet hardness, or stability. Crospovidone concentration and distribution are also important because rapid breakup is needed without producing floating particles or incomplete wetting.

Dissolution should be profiled across multiple pH conditions, including acidic media and physiologically relevant buffers. A generic product that matches only one dissolution medium may still encounter regulatory questions during comparative review.

Lactose sensitivity and global-market requirements

Adempas uses lactose monohydrate. A lactose-free formulation could target patients with lactose intolerance and simplify positioning in markets where lactose avoidance is commercially important. Suitable substitutes include:

• Mannitol.
• Dibasic calcium phosphate.
• Isomalt.
• Pregelatinized starch.
• Spray-dried cellulose-based blends.

A lactose-free composition can create a formulation patent opportunity, but a material change can also increase bioequivalence and stability work. Mannitol-based systems may improve mouthfeel but can alter tablet compactability and moisture behavior.

Lubrication

Magnesium stearate is effective but sensitive to blending time. Over-lubrication can reduce tablet tensile strength and slow dissolution. A controlled addition step, validated mixing endpoint, and in-process monitoring are important for a commercial process.

Alternative lubricants, such as sodium stearyl fumarate, could support a differentiated formulation. The commercial value is highest where the alternative improves dissolution or enables direct compression without compromising stability.

What formulation patents could protect a riociguat product?

The most defensible formulation claims would focus on measurable technical results rather than simply naming excipients. Potential claim themes include:

• A low-dose riociguat tablet with specified content-uniformity limits.
• A lactose-free formulation with equivalent dissolution.
• A composition using a defined superdisintegrant-to-active ratio.
• A tablet with improved stability under high humidity.
• A film-coated tablet with controlled photostability.
• A manufacturing process that reduces blend segregation.
• A multi-strength product using a common blend with strength-specific compression.

A formulation patent is more valuable when it establishes a relationship between composition and performance. Generic developers should avoid unnecessary infringement exposure by using excipient substitutions that deliver the same dissolution and stability profile without reproducing a narrow patented ratio.

What is the FDA exclusivity and Orange Book status of riociguat?

Riociguat's U.S. regulatory exclusivity has expired. FDA approval occurred on October 8, 2013. The five-year new chemical entity period therefore ended in October 2018. Orphan-drug exclusivity associated with the approved pulmonary hypertension indications did not create a permanent barrier to generic entry and has also expired for the original approval period (FDA, 2013).

Adempas is listed under NDA 204819. Patent protection, rather than NCE exclusivity, has been the principal U.S. entry barrier. Publicly associated U.S. patents include:

Patent	General subject matter	Strategic relevance
U.S. Patent No. 8,507,493	Riociguat and related substituted pyrazole compounds	Core compound and pharmaceutical protection
U.S. Patent No. 9,359,405	Riociguat-related pharmaceutical protection	Potential formulation or use barrier depending on listed claims
Additional Orange Book listings	Method-of-use and related protection	May affect ANDA certification and launch timing

The current FDA Orange Book should control any launch, Paragraph IV, or litigation analysis because listed patents, pediatric extensions, delistings, terminal disclaimers, and expiration dates can change. A commercial diligence review should evaluate each patent's listed expiration date, claim scope, maintenance status, and litigation history rather than relying on headline expiration estimates (FDA, 2024).

When does riociguat lose exclusivity and what generic entry risks exist?

The commercial opportunity is open because statutory exclusivity has expired, but patent certification remains important. An ANDA applicant may need to submit:

• Paragraph I certification if no patent is listed.
• Paragraph II certification if the patent has expired.
• Paragraph III certification accepting a later patent expiration date.
• Paragraph IV certification alleging that a listed patent is invalid, unenforceable, or not infringed.

A Paragraph IV notice can trigger Hatch-Waxman litigation and a potential 30-month stay of approval under applicable conditions. The practical launch date depends on the patent portfolio, the timing of notice, litigation outcome, settlement terms, and any authorized generic arrangement.

Generic launch scenarios

Scenario	Commercial outcome
No Paragraph IV challenge	Entry after listed patent barriers expire
Successful Paragraph IV challenge	Potential launch before nominal patent expiry
Invalidity or noninfringement settlement	Entry on an agreed date
Authorized generic agreement	Earlier competitive pressure with lower expected price erosion
Multiple generic approvals	Rapid price compression and payer substitution
Formulation-specific dispute	Narrower risk focused on excipient or process claims

Which companies are challenging riociguat exclusivity?

The identity and status of ANDA applicants, Paragraph IV notices, and litigation defendants must be confirmed through current FDA, PACER, and Orange Book records. Patent litigation can develop after a filing and may not be visible in product-level commercial databases.

The relevant competitive group includes:

• Large generic manufacturers with pulmonary hypertension portfolios.
• Specialty generic companies focused on complex oral dosage forms.
• Contract development and manufacturing organizations offering low-dose content-uniformity platforms.
• Regional manufacturers seeking approval outside the United States.

The most credible competitors will have prior experience with low-dose tablets, narrow dissolution specifications, and specialty-pharmacy distribution. A company with an approved sildenafil or tadalafil generic may have relevant pulmonary hypertension sales infrastructure but does not automatically possess a formulation advantage for riociguat.

How strong is the riociguat patent estate?

The estate is commercially meaningful but less difficult to design around than a biologic or complex inhaled product. Riociguat is a small molecule delivered in a conventional tablet. The strongest barriers are likely to be:

• Core compound claims, if still enforceable in a particular jurisdiction.
• Method-of-use claims covering CTEPH and PAH treatment.
• Patent claims tied to dosing or patient-selection restrictions.
• Formulation claims that require a specific excipient ratio or dissolution profile.

The weaker areas are likely to be routine excipient substitutions and conventional manufacturing steps that do not depend on a narrow inventive feature. The commercial strength of each patent depends on claim construction, prosecution history, enablement, written description, and prior-art exposure.

What biosimilar risk applies to riociguat?

Biosimilar risk does not apply to riociguat because it is a chemically synthesized small molecule, not a biologic. Competition proceeds through generic-drug pathways such as ANDA approval in the United States, not through the abbreviated biologics pathway.

This distinction reduces development complexity. A generic applicant does not need to establish biosimilarity, immunogenicity comparability, or biologic manufacturing consistency. The central requirements are pharmaceutical equivalence, bioequivalence, quality, stability, labeling, and patent certification.

What commercial opportunities exist for riociguat excipients?

Low-cost generic tablets

The largest opportunity is a standard immediate-release generic with a reliable low-dose manufacturing process. Cost advantages can come from:

• Direct compression.
• Common granulation across strengths.
• Reduced coating weight.
• High-yield continuous blending.
• Standardized excipient procurement.
• Regional manufacturing close to specialty-pharmacy markets.

Lactose-free and patient-segmented products

A lactose-free formulation could support differentiation where physicians or pharmacies value excipient exclusion. The opportunity is stronger outside markets where the reference formulation is broadly accepted and price dominates prescribing.

Orally disintegrating tablets

An orally disintegrating tablet could target patients with swallowing difficulty. The risks include moisture sensitivity, taste masking, dose loading, friability, and the need to demonstrate comparable exposure. Because riociguat is administered three times daily, administration convenience could have commercial value, but the product would require a clear benefit over conventional tablets.

Pediatric or lower-dose formulations

Pulmonary hypertension includes pediatric treatment contexts, but pediatric use is highly specialized and depends on labeling, clinical evidence, and dosing guidance. A lower-dose or dispersible formulation could address hospital and specialty-center needs, although it would require careful regulatory and clinical positioning.

Regional licensing and CDMO services

A company with a robust low-dose tablet platform could license:

• A riociguat formulation outside the United States.
• A lactose-free or ODT technology.
• A manufacturing process with validated content uniformity.
• A finished-dose product for specialty distributors.
• A common blend supporting multiple strengths.

The most valuable licensing asset is likely to be an approved or near-approved product rather than a broad excipient concept without comparative data.

How does riociguat compare with competing pulmonary hypertension drugs?

Drug	Class	Common dosage form	Generic competition	Excipient opportunity
Riociguat	Soluble guanylate cyclase stimulator	Immediate-release tablet	Strong potential after patent barriers	Low-dose uniformity, lactose-free, ODT
Sildenafil	PDE-5 inhibitor	Tablet, suspension	Mature generic market	Pediatric suspension and taste masking
Tadalafil	PDE-5 inhibitor	Tablet	Mature generic market	Conventional tablet efficiency
Selexipag	IP receptor agonist	Tablet	More specialized	Dose titration and formulation complexity
Treprostinil	Prostacyclin analogue	Injection, inhaled, oral forms	Delivery-system dependent	Device and stability technology

Riociguat's commercial differentiation is its mechanism and approved CTEPH indication. Its formulation opportunity is less technically complex than injectable or inhaled pulmonary hypertension products, but the market may experience meaningful price pressure once multiple generics enter.

What regulatory issues affect riociguat excipient commercialization?

FDA review will focus on pharmaceutical equivalence, bioequivalence, stability, impurity control, manufacturing consistency, and labeling. Key regulatory points include:

• Matching the reference product's dosage form and strength.
• Demonstrating dose-unit uniformity at 0.5 mg.
• Evaluating dissolution across relevant media.
• Controlling nitrosamine and other process-related impurities where applicable.
• Justifying excipient differences.
• Maintaining color differentiation across strengths.
• Addressing pregnancy-related labeling and restricted-use risk information.
• Preserving compatibility with the Adempas Risk Evaluation and Mitigation Strategy, or REMS, where applicable.

A formulation with a new excipient, unconventional delivery route, or materially different administration instructions would face a higher regulatory burden than a standard immediate-release tablet.

Key Takeaways

• Riociguat is a small-molecule pulmonary hypertension drug marketed as Adempas.
• U.S. NCE exclusivity expired in 2018, leaving patents and regulatory review as the principal entry considerations.
• The reference product uses a conventional immediate-release tablet with lactose, microcrystalline cellulose, crospovidone, hypromellose, sodium lauryl sulfate, and magnesium stearate.
• The 0.5 mg strength creates the greatest content-uniformity and segregation risk.
• The lowest-risk generic strategy is a Q1/Q2-matched immediate-release tablet with validated dissolution and low-dose blending controls.
• Lactose-free tablets, orally disintegrating tablets, and specialty low-dose platforms offer differentiated commercial opportunities.
• Riociguat has no biosimilar pathway because it is a chemically synthesized small molecule.
• Paragraph IV strategy, Orange Book patent status, and litigation timing determine the earliest U.S. generic launch date.
• The strongest commercial assets are an approved generic, a robust multi-strength manufacturing process, or a formulation with demonstrated patient or regulatory value.

FAQs

Is riociguat a biologic requiring biosimilar development?

No. Riociguat is a chemically synthesized small molecule. Competition uses generic-drug approval pathways, including ANDA submissions in the United States.

Can a generic riociguat tablet replace lactose with mannitol?

Potentially. The substitution requires formulation development, dissolution comparison, stability testing, content-uniformity control, and regulatory justification. Mannitol can change compactability, moisture response, and tablet mouthfeel.

What is the most important excipient issue for the 0.5 mg riociguat tablet?

Content uniformity is the central issue. The low active load increases the risk of blend segregation, sampling error, and individual-tablet assay variability.

Does riociguat have an extended-release formulation opportunity?

The marketed product is immediate release. An extended-release product would require a new clinical and regulatory strategy and would not be a straightforward generic substitution. The commercial rationale would need to come from reduced dosing frequency or improved tolerability.

Which riociguat formulation has the highest licensing value?

An approved or near-approved multi-strength generic with strong low-dose content uniformity, reliable dissolution, and a commercially differentiated excipient profile has the highest practical value. A lactose-free or orally disintegrating formulation may command additional value if it demonstrates a clear patient or market-access benefit.

References

1. Bayer. (2023). Adempas product information. Bayer AG.

2. U.S. Food and Drug Administration. (2013). FDA approves Adempas to treat pulmonary hypertension. U.S. Department of Health and Human Services.

3. U.S. Food and Drug Administration. (2023). Adempas (riociguat) prescribing information. U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

5. U.S. Patent and Trademark Office. (2009). U.S. Patent No. 8,507,493: Substituted pyrazole compounds. U.S. Department of Commerce.

6. U.S. Patent and Trademark Office. (2016). U.S. Patent No. 9,359,405. U.S. Department of Commerce.